
Founder & Managing Partner
Neta Kela, PhD
Copenhagen
Leads PXM across Scout, Fund, Operate and Transact, with a focus on EU and US life-science regulatory strategy, funding and partnering.
Dr. Neta Kela is a commercialization and business development leader in life sciences, with deep expertise in biologics, cell therapy, antibody therapeutics, and immunology. She combines rigorous scientific training with a track record of translating life science innovation across development stages into high value pharma partnerships and strategic collaborations. At PXM, Neta leads mandates across pipeline positioning, partnering strategy, and commercialization, aligning biotech programs with pharma priorities and driving collaborations that create lasting value. She serves as Chief Commercialization Advisor at the University of Copenhagen and mentors companies through the SPARK program. Neta completed postdoctoral training at Stanford University, where she was awarded the McCormick Fellowship for Women in Science.
PXM on LinkedInFocus areas
- EU and US regulatory strategy
- EU non-dilutive funding
- Licensing and partnering
- Biologics, cell therapy and antibody therapeutics
- Commercialization strategy
Articles by Neta Kela
- FDA National Priority Voucher (CNPV): Should You Apply?
October 2, 2026
- The Delaware Flip: How European Biotechs Win US VC Funding
October 2, 2026
- Biotech M&A Targets in 2026: Where Pharma Is Really Buying
October 2, 2026
- Horizon Europe Health 2027 Calls Open Oct 29: Biotech Guide
October 2, 2026
- EIC Accelerator 2026 Cut-off and IHI Call 13: Funding Watch
October 2, 2026
- Your CDMO Just Became a Regulatory Risk: BIOSECURE and FDA PreCheck Explained
September 3, 2026
- How to Prepare for an FDA Pre-IND Meeting (and What Most Teams Get Wrong)
August 29, 2026
- IND-Enabling Studies: What a First-in-Human Package Actually Requires
August 29, 2026
- CDMO Selection for Biotech: The Criteria That Actually Predict Success
August 29, 2026
- Non-Dilutive Funding for Biotech in 2026: A Practical Guide to EU and UK Grants
August 27, 2026
- 5 CMC Strategy Mistakes That Delay IND Filings — And How to Avoid Them
August 7, 2026
- 3 Regulatory Mistakes That Keep Coming Up in Biotech
March 30, 2026
- Bluebird Bio's Three-Year FDA Delay: The CMC Trap That Stalls Gene Therapy Programs
April 24, 2025
- UK Biotech Companies: How to Navigate EU and US Market Entry Post-Brexit
March 30, 2025
- From UK to Global: A Commercialization Roadmap for British Biotech Companies
March 25, 2025
- How to Build a Commercialization Strategy for Biotech Companies
March 20, 2025
- EU vs US Market Access: Key Differences for Pharma Companies
March 15, 2025
- AI-Designed Antibodies Are Moving from Concept to Reality
March 10, 2025
- Cell Therapy Companies: Manufacturing May Become Your Biggest Bottleneck
March 5, 2025
- A Regulatory Inflection Point for Biologics – Will You Lead or React?
March 1, 2025